Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents

AIDS Research and Human Retroviruses

Volumn 13, Issue 8, 1997, Pages 695-705

  Hara, Hiroto ^a   Fujihashi, Toshiaki ^b,c   Sakata, Toshiya ^b,c   Kaji, Akira ^a   Kaji, Hideko ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TSUMURA AND CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1506; 1737; 1738; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; 5,6,7 TRIMETHOXY 4 (3,4,5 TRIMETHOXYPHENYL) 1,3,3A,4,9,9A HEXAHYDRONAPHTHO[2,3 C]THIOPHENE; 7 METHOXY 5,6 METHYLENEDIOXY 4 (4 BENZYLOXY 3 METHOXYPHENYL) 1,3,3A,4,9,9A HEXAHYDRONAPHTHO[2,3 C]THIOPHENE; ANTIVIRUS AGENT; FOSCARNET; GOMISIN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030992580     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.695     Document Type: Article

References (64)

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, and Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
2. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
3. De Clercq E: HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992;8:119-134.
4. Mitsuya H, Weinhold KJ, Furman PA, St. Clair MH, Nusinoff-Lehrman S, Gallo RC, Bolognesi D, Barry DW, and Broder S: 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
5. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno C-F, Walker RT, and Miyasaka T: Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989;165:1375-1381.
6. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-197.
7. Yarchoan R and Broder S: Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders: a progress report. N Engl J Med 1987;316:557-564.
8. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, and Griffin JL: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-1105.
9. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
10. Kukla MJ, Breslin HJ, Pauwels R, Fedde CL, Miranda M, Scott MK, Sherrill RG, Raeymaekers A, Van Gelder J, Andries K, Janssen MAC, De Clercq E, and Janssen PAJ: Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. J Med Chem 1991;34: 746-751.
11. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E, and Janssen PAJ: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London) 1990;343:470-474.
12. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosehthal AS, Faanes R, Eckner RJ, Koup RA, and Sullivan JL: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-1413.
13. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA, and Stern AM: Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-6867.
14. Chimirri A, Grasso S, Monforte A-M, Monforte P, and Zappala M: Anti-HIV agents. I. Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-(a)]benzimidazoles. Farmaco 1991;46: 817-823.
15. Chimirri A, Grasso S, Monforte A-M, Monforte P, and Zappala M: Anti-HIV agents. II. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-(a)]benzimidazoles. Farmaco 1991;46: 925-933.
16. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme A-M, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, De Clercq E, and Janssen PAJ: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993;90:1711-1715.
17. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, McMahon JB, Currens MJ, Buckheit RW, Hughes SH, Cragg GM, and Boyd MR: The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 1992;35:2735-2743.
18. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashima H, Mori S, Shigeta S, Walker RT, and Miyasaka T: Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1991;88:2356-2360.
19. McMahon JB, Gulakowski RJ, Weislow OS, Schultz RJ, Narayanan VL, Clanton DJ, Pedemonte R, Wassmundt FW, Buckheit RW, Decker WD, White EL, Bader JP, and Boyd MR: Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:754-760.
20. Gao Q, Parniak MA, Gu Z, and Wainberg MA: Generation of nucleoside-resistant variants for HIV-1 by in vitro selection in the presence of AZT of DDI but not by combinations. Leukemia 1993;6:192S-195S.
21. Chow Y-K, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, and D'Aquila RT: Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (London) 1993;361:650-654.
22. Buckheit RW, Germany-Decker J, Hollingshead MG, Allen LB, Shannon WM, Janssen PAJ, and Chirigos MA: Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents. AIDS Res Hum Retroviruses 1993;9:1097-1106.
23. Johnson VA, Merrill DP, Chou T-C, and Hirsch MS: Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-αA against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992;166: 1143-1146.
24. Brewer CF, Loike JD, Horwitz SB, Sternlicht H, and Gensler WJ: Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly. J Med Chem 1979;22:215-221.
25. Loike JD and Horwitz SB: Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 1976;15: 5443-5448.
26. Markkanen T, Mäkinen ML, Maunuksela E, and Himanen P: Podophyllotoxin lignans under experimental antiviral research. Drugs Exp Clin Res 1981;7:711-718.
27. MacRae WD, Hudson JB, and Towers GHN: The antiviral action of lignans. Planta Medica 1989;55:531-535.
28. Schröder HC, Merz H, Steffen R, Müller WEG, Sarin PS, Trumm S, Schulz J, and Eich E: Differential in vitro anti-HIV activity of natural lignans. Z Naturforsch 1990;45c:1215-1221.
29. Higuchi H, Mori K, Kato A, Ohkuma T, Endo T, Kaji H, and Kaji A: Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. Antiviral Res 1991;15:205-216.
30. Ogata T, Higuchi H, Mochida S, Matsumoto H, Kato A, Endo T, Kaji A, and Kaji H: HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri. AIDS Res Hum Retroviruses 1992;8:1937-1944.
31. Fujihashi T, Sakata T, Kaji A, and Kaji H: Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus. Biochem Biophys Res Commun 1994;203:1244-1250.
32. Fujihashi T, Sakata T, Kaji A, and Kaji H: Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus-1. AIDS Res Hum Retroviruses 1995;11:461-471.
33. Fujihashi T, Hara H, Sakata T, Mori K, Higuchi H, Tanaka A, Kaji H, and Kaji A: Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2000-2007.
34. Tanaka M, Sakata T, Ikeya Y, Wakamatsu T, Fujihashi T, Kaji A, and Kaji H: Tetrahydronaphthalene derivative, process for producing the same, and retrovirus infection remedy containing the same as active ingredient. International Patent PCTJP94 01083 (WO9501950), 1994.
35. Harada S, Koyanagi Y, and Yamamoto N: Infection of HTLV-III/LAV in HTLV-1-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985;229:563-566.
36. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, and Glader BE: Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984;44:5657-5660.
37. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, and Hunt RD: Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985;228:1201-1204.
38. Schulz TF, Whitby D, Hoad JG, Corrah T, Whittle H, and Weiss RA: Biological and molecular variability of human immunodeficiency virus type 2 isolates from the Gambia. J Virol 1990;64:5177-5182.
39. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA, and Goldman ME: Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-4892.
40. Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S, and Griffin J: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245.
41. Mellors JW, Im G-J, Tramontane E, Winkler SR, Medina DJ, Dutschman GE, Bazmi HZ, Piras G, Gonzalez CJ, and Cheng Y-C: A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl) imida zo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TTBO R82150). Mol Pharmacol 1993;43:11-16.
42. Otto MJ, Reid CD, Garber S, Lam PY, Scarnati H, Bacheler LT, Rayner MM, and Winslow DL: In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother 1993;37:2606-2611.
43. Clavel F, Guyader M, Guétard D, Sallé M, Montagnier L, and Alizon M: Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature (London) 1986;324:691-695.
44. Hizi A, McGill C, and Hughes SH: Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci USA 1988;85:1218-1222.
45. Boyer PL, Currens MJ, McMahon JB, Boyd MR, and Hughes SH: Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1993;67:2412-2420.
46. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
47. Coates JAV, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM, and Penn CR: The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-205.
48. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
49. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatsuki K, and Putney S: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988;62:2107-2114.
50. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M, and Picker D: Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992;89:5286-5290.
51. Gao Q, Gu Z, Parniak MA, Li X, and Wainberg MA: In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 1992;66:12-19.
52. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR Jr, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, and Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (London) 1985;313:277-284.
53. Baba M, Pauwels R, Balzarini J, Arnout J, and Desmyter J: Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132-3136.
54. De Clercq E: HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994;47:155-169.
55. Shih C-K, Rose JM, Hansen GL, Wu JC, Bacolla A, and Griffin JA: Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 1991;88:9878-9882.
56. De Vreese K, Debyser Z, Vandamme A-M, Pauwels R, Desmyter J, De Clercq E, and Anné J: Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology 1992;188:900-904.
57. Balzarini J, Karlsson A, and De Clercq E: Human immunodeficiency virus type 1 drug resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol Pharmacol 1993;44:694-701.
58. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J, Tarpley WG, and De Clercq E: Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 1993;67:5353-5359.
59. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH, and Arnold E: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci USA 1993;90:6320-6324.
60. Jacobo-Molina A and Arnold E: HIV reverse transcriptase structure-function relationships. Biochemistry 1991;30:6351-6361.
61. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PAJ, and Arnold E: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994;243:369-387.
62. Barber AM, Hizi A, Maizel JV Jr, and Hughes SH: HIV-1 reverse transcriptase: Structure predictions for the polymerase domain. AIDS Res Hum Retroviruses 1990;6:1061-1072.
63. Sardana VV, Emini EA, Gotlib L, Graham DJ, Lineberger DW, Long WJ, Schlabach AJ, Wolfgang JA, and Condra JH: Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem 1992;267:17526-17530.
64. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.